Radio and PodcastRadio and PodcastLive Radio & Podcasts
Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech artwork
Science & Medicine

Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech

BioCentury This Week by BioCentury

Jul 6, 202633:44Science & Medicine

Novartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech Myricx Pharma. On the latest episode of the BioCentury This Week podcast, BioCentury’s analysts discuss how...

About This Episode

Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech is an episode from BioCentury This Week by BioCentury. Novartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech...

Podcast

This episode belongs to BioCentury This Week.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Jul 6, 2026, 33:44 long, audio available.

Related Episodes

Continue listening to more episodes from BioCentury This Week.